Journal Information
Vol. 28. Issue 4.
Pages 179-185 (May 1992)
Share
Share
Download PDF
More article options
Vol. 28. Issue 4.
Pages 179-185 (May 1992)
Full text access
Factores pronósticos en el carcinoma microcítico de pulmón
Prognostic factors in microcytic carcinoma of the lung
Visits
3699
J. Sánchez de Cos Escuín, F. Masa Jiménez, J.L. de la Cruz Ríos, M.C. Vergara Fiordia
Unidad de Neumología. Servicio de Medicina Interna. Hospital de la S.S. San Pedro de Alcántara. Cáceres
This item has received
Article information
Abstract
Bibliography
Download PDF
Statistics

En 71 pacientes con carcinoma microcítico de pulmón (30 con enfermedad limitada y 41 con enfermedad diseminada), se analizó la asociación con el tiempo de supervivencia y la respuesta al tratamiento de las siguientes variables pretrata-miento: edad, grado ECOG, estadio, presencia de adenopatías mediastínicas, síndrome de vena cava superior, metástasis óseas, hepáticas o encefálicas; número de metástasis, concentración de albúmina sérica, hematocrito y pauta de poliqui-mioterapia aplicada.

En el conjunto total de casos, el análisis univariado mostró mayor supervivencia asociada a los siguientes parámetros: estadio enfermedad limitada (EL), poliquimioterapia (PQT) con carboplatino (CPT) y vp-16, grados ECOG 0-1, concentración normal de albúmina sérica y ausencia de afección mediastínica. Los dos primeros conservaron valor pronóstico independiente en el modelo multivariado de Cox (EL, p=0,012; PQT, p=0,021). La remisión completa fue significativamente más frecuente en estadio EL (p=0,045).

En estadio enfermedad limitada, sólo la afección mediastínica conllevó una supervivencia más corta (p=0,016). En estadio de enfermedad diseminada, únicamente la presencia de metástasis encefálica mantuvo valor pronóstico en el modelo multivariado.

In a series of 71 patients with microcytic carcinoma of the lung (limited disease in 30 patients and disseminated disease in 41) we analyzed the association between survival time and response to treatment with the following pretreatment variables: age, ECOG degree, stage, presence of mediastinal adenopathies, superior vena cava syndrome, metastases to bones, liver, or brain, number of metastases, level of serum albumin, hematocrit, and type of polychemotherapy used. In the overall series of patients univariate analysis revealed a higher survival associated to the following parameters: stage of the limited disease, polychemotherapy with carboplatin and vp-16, ECOG degrees 0-1, normal level of serum albumin, and absence of mediastinal involvement. The first two variables had an independent prognostic valué in Cox multivariate model (p=0.012 and p=0.021, respectively). Complete remission was significantly more frequent in cases with limited disease (p=0.045). In cases of limited disease only the presence of mediastinal involvement induced a shorter survival (p=0.016). During the stage of disseminated disease only the presence of encephalic metastases had a prognostic valué in the multivariate analysis model.

Full text is only aviable in PDF
Bibliografía
[1.]
B.E. Johnson, J.D. Minnu.
Small cell lung cancer.
Pulmonary diseases and disorders., 2nd ed, pp. 1971-1982
[2.]
J. Sánchez de Cos, J. Redondo, A. Sever, A. García, J.L. De la Cruz, F. Masa.
Carcinoma broncopulmonar Estudio epidemiológicoclínico de 157 casos.
Atención Primaria, 6 (1989), pp. 304-311
[3.]
García Conde J, Alberola V, Lluch A. Avances en el tratamiento del carcinoma microcítico de pulmón. En:Avances en Medicina, Interna, Ediciones Aran : Madrid 1988:79-88
[4.]
J. Abrams, L.A. Doyle, J. Aisner.
Staging, prognosis factors and special considerations in small cell lung cancer.
Semin Oncol, 15 (1988), pp. 261-277
[5.]
J. Sánchez de Cos, F. Masa, J.L. De la Cruz, A. Martínez.
Poliquimioterapia secuencial (carboplatino/Vp-16) versus alternante (carboplatino/Vp-16 y ciclofosfamida/vincristina/adriamicina) en el carcinoma microcítico de pulmón.
Arch Bronconeumol, 26 (1990), pp. 292-296
[6.]
D.G. Kleinbaum, L.L. Kupper, K.E. Muller.
Selecting the best regression equation.
Applied regression analysis and other multivariable methods, 2.a, pp. 314-341
[7.]
D.R. Cox.
Regression models and life-tables.
JR Statistical Soc, 34 (1972), pp. 187-220
[8.]
D.N. Carney, L. Grogan, F. Smit, P. Harford, H.H. Berendsen, P.E. Postmus.
Single-agent oral etoposide for elderly small cell lung cancer patients.
Semin Oncol, 17 (1990), pp. 49-53
[9.]
K. Osterlind, P.K. Andersen.
Prognostic factors in small cell lung cancer: multivariate model based on 778 patients treated with chemotherapy with or without irradiation.
Cancer Res, 46 (1986), pp. 4.189-4.194
[10.]
J.D. Hainsworth, D.H. Johnson, R.V. Farese, J.W. Macey, W.K. Vaughn, F.A. Greco.
Limited stage small cell lung cancer: analysis of clinical prognostic factors.
South Med J, 80 (1987), pp. 1.508-1.512
[11.]
D. Spiegelman, L.H. Maurer, J.H. Ware, et al.
Prognostic factors in small cell carcinoma of the lung: an analysis of 1521 patients.
J Clin Oncol, 7 (1989), pp. 344-354
[12.]
M.H. Cohen, R. Makuch, A. Jonhston-Early, et al.
Laboratory parameters as an alternative to performance status in prognostic stratification of patients with small cell lung cancer.
Cancer Treat Rep, 65 (1981), pp. 187-195
[13.]
R.L. Souhami, I. Bradbury, D.M. Geddes, S.G. Spiro, P.G. Harper, J.S. Tobias.
Prognostic significance of laboratory parameters measured at diagnosis in small cell carcinoma of the lung.
Can cer Res, 45 (1985), pp. 2.878-2.882
[14.]
P. Santabárbara.
Evolución y pronóstico en el cáncer de pulmón.
Cáncer de pulmón, pp. 88-98
[15.]
R. Amagada, H. de The, T. Le Chevalier, et al.
Limited small cell lung cancer: possible prognostic impact of initial chemotherapy doses.
Bull Cancer (Paris), 76 (1989), pp. 604-615
[16.]
T. Cerny, V. Blair, H. Anderson, V. Bramwell, N. Thatcher.
Pretreatment prognostic factors and scoring system in 407 small cell lung cancer patients.
Int J Cancer, 39 (1987), pp. 146-149
[17.]
M.D. Vincent, S.E. Ashley, I.E. Smith.
Prognostic factors in small cell lung cancer: A simple prognostic index is better than conventional staging.
Eur J Cancer Clin Oncol, 23 (1987), pp. 1.589-1.599
[18.]
M. Wolf, K. Havemann, R. Holle, P. Drings, K. Hans, M. Schroeder.
Rezidivhäufigkeit und langzeit Uberleben beim kleinzelligen Bronchialkarcinom.
Onkologie, 10 (1987), pp. 357-366
[19.]
T. Shinkai, M. Sakuri, K. Eguchi, et al.
Prognostic factors in small cell lung cancer: multivariate analysis in the National Cancer Center Hospital.
Jpn J Clin Oncol, 19 (1989), pp. 135-141
[20.]
B.E. Johnson, S.M. Steinberg, R. Phelps, M. Edison, S.R. Veach, D.C. Ihde.
Female patients with small cell lun cancer live longer than male patients.
Am J Med, 85 (1988), pp. 194-196
[21.]
J.P.A. Crown, A.P. Chahinian, I.S. Jaffrey, O.J. Glidewell, M. Kaneko, J.F. Holland.
Predictors of 5-year survival and curability in small cell lung cancer.
Cancer, 66 (1990), pp. 382-386
Copyright © 1992. Sociedad Española de Neumología y Cirugía Torácica
Archivos de Bronconeumología
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?